Show table of contents · 8 sections▾
This is a plain-English explainer, not legal advice. Only a licensed attorney representing you can evaluate the specific facts of your case.
The Tepezza Litigation at a Glance
Tepezza (teprotumumab-trbw) is an FDA-approved infusion medication marketed for thyroid eye disease (TED) since 2020. Plaintiffs allege Horizon Therapeutics (acquired by Amgen in 2023) failed to adequately warn about the risk of permanent hearing loss, tinnitus, and other auditory injuries associated with treatment.
MDL 3079 Formation and Status
The JPML consolidated federal Tepezza cases in MDL 3079 in the Northern District of Illinois before Judge Thomas M. Durkin in June 2023. As of 2026:
- Thousands of cases consolidated.
- Bellwether selection and trials advancing.
- Case-specific discovery underway.
Alleged Failure to Warn
Plaintiffs allege that clinical trial data and post-market surveillance showed meaningful hearing-related adverse events, but the original label understated the frequency and permanence of these injuries. Some warnings have been strengthened over time under FDA pressure.
Common Injuries
- Permanent sensorineural hearing loss.
- Tinnitus (ringing in the ears).
- Autophony (hearing one's own voice too loudly).
- Vestibular disturbance.
Documentation for a Case
- Confirmed Tepezza use with treatment records.
- Audiology testing before, during, and after treatment.
- Documented persistent hearing loss or tinnitus.
- MDL-experienced counsel.
Funding Availability
Pre-settlement funding is available for filed MDL cases with documented Tepezza use and audiology-confirmed hearing injury.
The Bottom Line
The Tepezza MDL is an active pharmaceutical mass tort with growing case numbers. If you took Tepezza and developed hearing loss or tinnitus, consult an MDL-experienced attorney and obtain audiology testing to document the injury.
At Instabridge Funding, we work with plaintiff attorneys across all fifty states — attorney-founded, non-recourse, and transparently priced. If your case is filed and you would like a fair pre-settlement offer, apply through our portal and your attorney will hear back within one business day.
Frequently asked questions
An FDA-approved infusion medication for thyroid eye disease, marketed by Horizon Therapeutics (now Amgen).
Permanent sensorineural hearing loss, tinnitus, autophony, and vestibular disturbance documented by audiology testing.
Pre-treatment baseline audiology (where available) compared to post-treatment testing showing new or worsened hearing deficits.
Thousands as of 2026 and growing.
Northern District of Illinois before Judge Thomas M. Durkin.
Yes, for filed cases with documented Tepezza use and audiology-confirmed injury.
Mild cases still have case value but less than severe or permanent complete hearing loss. Talk to your attorney.
Bellwether verdicts expected 2026–2027 with global settlement possible 2027–2029.
